Disc Medicine price target lowered to $100 from $120 at BMO Capital

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Disc Medicine (IRON) to $100 from $120 but keeps an Outperform rating on the shares. After meeting with Disc management, it remains somewhat unclear how FDA came to the conclusion that PPIX reduction was not associated with clinical benefit, the analyst tells investors in a research note. The firm adds it was encouraged to learn Disc expects to meet with the agency in a Type A meeting and could provide APOLLO data by Q4 of this year.